Pyxis Oncology (PYXS) Cash & Equivalents (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Cash & Equivalents data on file, last reported at $15.4 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $15.4 million, down 20.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $15.4 million (down 20.8% YoY), and the FY2025 annual result was $15.4 million, down 20.8% from the prior year.
• Cash & Equivalents climbed to $15.4 million in Q4 2025 per PYXS's latest filing, from $8.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $274.7 million in Q4 2021 and troughed at $8.9 million in Q3 2025.
• A 5-year average of $88.8 million and a median of $26.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2023: Cash & Equivalents soared 1086.88% in 2021, then plunged 94.61% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $274.7 million in 2021, then sank by 34.74% to $179.3 million in 2022, then sank by 94.61% to $9.7 million in 2023, then surged by 101.5% to $19.5 million in 2024, then slipped by 20.8% to $15.4 million in 2025.
• Business Quant data shows PYXS's Cash & Equivalents at $15.4 million in Q4 2025, $8.9 million in Q3 2025, and $10.7 million in Q2 2025.